Comparison of healthcare resource utilization and costs of patients with HR+/HER2- advanced breast cancer treated with ribociclib versus other CDK4/6 inhibitors

References

• Mariotto AB, Etzioni R, Hurlbert M, et al. Estimation of the number of women living with metastatic breast cancer in the united states. Cancer Epidemiol Biomarkers Prev. 2017;26:809–815.
   PubMed Web of Science ®Google Scholar
• Bonotto M, Gerratana L, Iacono D, et al. Treatment of metastatic breast cancer in a real-world scenario: is progression-free survival with first line predictive of benefit from second and later lines? Oncologist. 2015;20(7):719–724.
   PubMed Web of Science ®Google Scholar
• De Mattos-Arruda L, Cortes J. Advances in first-line treatment for patients with HER-2+ metastatic breast cancer. Oncologist. 2012;17:631–644.
   PubMed Web of Science ®Google Scholar
• Redig AJ, McAllister SS. Breast cancer as a systemic disease: a view of metastasis. J Intern Med. 2013;274:113–126.
   PubMed Web of Science ®Google Scholar
• Roche H, Vahdat LT. Treatment of metastatic breast cancer: second line and beyond. Ann Oncol. 2011;22:1000–1010.
   PubMed Web of Science ®Google Scholar
• Cadoo KA, Fornier MN, Morris PG. Biological subtypes of breast cancer: current concepts and implications for recurrence patterns. Q J Nucl Med Mol Imaging. 2013;57:312–321.
   PubMed Web of Science ®Google Scholar
• Fogli S, Del Re M, Curigliano G, et al. Drug-drug interactions in breast cancer patients treated with CDK4/6 inhibitors. Cancer Treat Rev. 2019;74:21–28.
   PubMed Web of Science ®Google Scholar
• Goldschmidt D, Dalal AA, Romdhani H, et al. Current treatment patterns among postmenopausal women with HR+/HER2- metastatic breast cancer in US community oncology practices: an observational study. Adv Ther. 2018;35:482–493.
   PubMed Web of Science ®Google Scholar
• Sobhani N, D’Angelo A, Pittacolo M, et al. Updates on the CDK4/6 inhibitory strategy and combinations in breast cancer. Cells. 2019;8(4):321.
   Web of Science ®Google Scholar
• U.S. Food and Drug Administration. 2017. “Palbociclib (IBRANCE)”; [cited 2019 July 23]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/palbociclib-ibrance.
   Google Scholar
• U.S. Food and Drug Administration. 2017. “Ribociclib (Kisqali)”; [cited 2019 July 23]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209092s003lbl.pdf.
   Google Scholar
• U.S. Food and Drug Administration. 2018. “FDA approves abemaciclib as initial therapy for HR-positive, HER2-negative metastatic breast cancer.”; [cited 2019 July 23]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-abemaciclib-initial-therapy-hr-positive-her2-negative-metastatic-breast-cancer.
   Google Scholar
• Tripathy D, Im SA, Colleoni M, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018;19(7):904–915.
   PubMed Web of Science ®Google Scholar
• Loibl S, Turner NC, Ro J, et al. Palbociclib combined with fulvestrant in premenopausal women with advanced breast cancer and prior progression on endocrine therapy: PALOMA-3 Results. Oncologist. 2017;22:1028–1038.
   PubMed Web of Science ®Google Scholar
• Sledge GW, Jr., Toi M, Neven P, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017;35(25):2875–2884.
   PubMed Web of Science ®Google Scholar
• Messina C, Cattrini C, Buzzatti G, et al. CDK4/6 inhibitors in advanced hormone receptor-positive/HER2-negative breast cancer: a systematic review and meta-analysis of randomized trials. Breast Cancer Res Treat. 2018;172:9–21.
   PubMed Web of Science ®Google Scholar
• Yardley DA. MONALEESA clinical program: a review of ribociclib use in different clinical settings. Future Oncol. 2019;15(23):2673–2686.
   PubMed Web of Science ®Google Scholar
• Hortobagyi GN. Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial. Breast Cancer Res. 2018;20:123.
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Neven P, Chia S, et al. Overall survival with ribociclib plus fulvestrant in advanced breast cancer. N Engl J Med. 2020;382:514–524.
   PubMed Web of Science ®Google Scholar
• Im SA, Lu YS, Bardia A, et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med. 2019;381:307–316.
   PubMed Web of Science ®Google Scholar
• Goetz MP, Toi M, Campone M, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;35:3638–3646.
   PubMed Web of Science ®Google Scholar
• Turner NC, Slamon DJ, Ro J, et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med. 2018;379(20):1926–1936.
   PubMed Web of Science ®Google Scholar
• Iwata H, Im SA, Masuda N, et al. PALOMA-3: phase III trial of fulvestrant with or without palbociclib in premenopausal and postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer that progressed on prior endocrine therapy-safety and efficacy in asian patients. J Glob Oncol. 2017;3:289–303.
   PubMed Web of Science ®Google Scholar
• Zhang B, Long EF. Cost-effectiveness analysis of palbociclib or ribociclib in the treatment of advanced hormone receptor-positive, HER2-negative breast cancer. Breast Cancer Res Treat. 2019;175:775–779.
   PubMed Web of Science ®Google Scholar
• Giuliani J, Bonetti A. The introduction of a third CDK4/6 inhibitor does not change the cost-effectiveness profile in first and subsequent-lines after progression or relapse during previous endocrine therapy in patients with hormone receptor positive (HR+)/human epidermal receptor-2 negative (HER-2) advanced or metastatic breast cancer. J Oncol Pharm Pract. 2020;26:1486–1491.
   PubMed Web of Science ®Google Scholar
• Le V, Zhong L, Narsipur N, et al. Cost-effectiveness of ribociclib plus endocrine therapy versus placebo plus endocrine therapy in HR-positive, HER2-negative breast cancer. J Manag Care Spec Pharm. 2021;27:327–338.
   PubMed Web of Science ®Google Scholar
• Loke L, Lee SC, Pearce F, et al. Cost-effectiveness of ribociclib as initial treatment for premenopausal women with advanced breast cancer in Singapore. Cancer Rep. 2021;4:e1308.
   Google Scholar
• Dalal AA, Gauthier G, Gagnon-Sanschagrin P, et al. Treatment and monitoring patterns among premenopausal women with HR+/HER2- advanced breast cancer. Adv Ther. 2018;35:1356–1367.
   PubMed Web of Science ®Google Scholar
• Hurvitz S, Guerin A, Brammer M, et al. Investigation of adverse-event-related costs for patients with metastatic breast cancer in a real-world setting. Oncologist. 2014;19:901–908.
   PubMed Web of Science ®Google Scholar
• Ramsey SD, Martins RG, Blough DK, et al. Second-line and third-line chemotherapy for lung cancer: use and cost. Am J Manag Care. 2008;14:297–306.
   PubMed Web of Science ®Google Scholar
• Seal BS, Sullivan SD, Ramsey S, et al. Medical costs associated with use of systemic therapy in adults with colorectal cancer. J Manag Care Pharm. 2013;19:461–467.
   PubMed Web of Science ®Google Scholar
• Zhu J, Sharma DB, Gray SW, et al. Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced non-small cell lung cancer. JAMA. 2012;307:1593–1601.
   PubMed Web of Science ®Google Scholar
• Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43:1130–1139.
   PubMed Web of Science ®Google Scholar
• Hainmueller J. Entropy balancing for causal effects: a multivariate reweighting method to produce balanced samples in observational studies. Polit Anal. 2012;20(1):25–46.
   Web of Science ®Google Scholar
• Hainmueller J, Xu Y. ebalance: a Stata package for entropy balancing. J Stat Soft. 2013;54(7):v054.i07.
   Web of Science ®Google Scholar
• Adhikary SD, Liu WM, Memtsoudis SG, et al. Body mass index more than 45 kg/m(2) as a cutoff point Is associated with dramatically increased postoperative complications in total knee arthroplasty and total hip arthroplasty. J Arthroplasty. 2016;31:749–753.
   PubMed Web of Science ®Google Scholar
• Bahler C, Schoepfer AM, Vavricka SR, et al. Chronic comorbidities associated with inflammatory bowel disease: prevalence and impact on healthcare costs in Switzerland. Eur J Gastroenterol Hepatol. 2017;29:916–925.
   PubMed Web of Science ®Google Scholar
• Ghate SR, Ionescu-Ittu R, Burne R, et al. Healthcare resource utilization in patients with metastatic melanoma receiving first-line therapy with dabrafenib + trametinib versus nivolumab or pembrolizumab monotherapy. Curr Med Res Opin. 2018;34:2169–2176.
   PubMed Web of Science ®Google Scholar
• Heider D, Matschinger H, Meid AD, et al. Service use, costs, and adverse events associated with potentially inappropriate medication in old age in Germany: retrospective matched cohort study. Drugs Aging. 2017;34:289–301.
   PubMed Web of Science ®Google Scholar
• Petrelli F, Ghidini A, Pedersini R, et al. Comparative efficacy of palbociclib, ribociclib and abemaciclib for ER + metastatic breast cancer: an adjusted indirect analysis of randomized controlled trials. Breast Cancer Res Treat. 2019;174:597–604.
   PubMed Web of Science ®Google Scholar
• Sledge GW, Frenzel M. Analysis of overall survival benefit of abemaciclib plus fulvestrant in hormone receptor-positive, ERBB2-negative breast cancer-reply. JAMA Oncol. 2020;6(7):1122–1123.
   PubMed Web of Science ®Google Scholar
• Dieguez G, Ferro C, Pyenson B. 2017. “Milliman research report: a multiyear look at the cost burden of cancer”; [cited 2021 Jun 5]. Available from: https://milliman-cdn.azureedge.net/-/media/milliman/importedfiles/uploadedfiles/insight/2017/cost-burden-cancer-care.ashx.
   Google Scholar
• Vera-Llonch M, Weycker D, Glass A, et al. Healthcare costs in women with metastatic breast cancer receiving chemotherapy as their principal treatment modality. BMC Cancer. 2011;11:250.
   PubMed Web of Science ®Google Scholar
• Sorensen SV, Goh JW, Pan F, et al. based cost-of-illness model for metastatic breast cancer in the United States. Int J Technol Assess Health Care. 2012;28:12–21.
   PubMed Web of Science ®Google Scholar
• Montero AJ, Eapen S, Gorin B, et al. The economic burden of metastatic breast cancer: a U.S. managed care perspective. Breast Cancer Res Treat. 2012;134:815–822.
   PubMed Web of Science ®Google Scholar
• Burton T, Byfield SD, Smith GL, et al. Clinical and economic outcomes by first-line treatment among women with HR+/HER2- metastatic breast cancer in a large US health plan database. Curr Med Res Opin. 2016;32(8):1417–1423.
   PubMed Web of Science ®Google Scholar
• Centers for Medicare & Medicaid Services (CMS). 2021. “Oncology care model”; [cited 2021 Jan 28]. Available from: https://innovation.cms.gov/innovation-models/oncology-care.
   Google Scholar
• Centers for Medicare & Medicaid Services (CMS). 2017. “CMS Star Rating Program and our network providers"; [cited 2021 Jan 28]. Available from: https://www.ibx.com/documents/35221/56671/cms-star-rating-provider-guide.pdf/4522db52-d921-6156-db05-f392f9e08da6?t=1580918398627.
   Google Scholar
• Association for Clinical Oncology 2020. "Quality Oncology Practice Initiative (QOPI®) Certification Program"; [cited 2021 Jan 28]. Available from: https://practice.asco.org/quality-improvement/quality-programs/qopi-certification-program.
   Google Scholar